
A Next-Generation Therapy
The ALK+ NSCLC treatment landscape is continuously evolving, and LORBRENA® is one of the latest ALK inhibitor therapies. It is a prescription medicine for people living with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer (NSCLC) that has spread to other parts of the body and their NSCLC is no longer responding to alectinib or ceritinib, or crizotinib and at least 1 other ALK inhibitor medicine.
LORBRENA is available in a 100-mg strength tablet and a 25-mg strength tablet.